药品详细
Sulfamoxole(Sulfamoxole)
化学结构式图
中文名
Sulfamoxole
英文名
Sulfamoxole
分子式
C11H13N3O3S
化学名
4-amino-N-(dimethyl-1,3-oxazol-2-yl)benzene-1-sulfonamide
分子量
Average: 267.304
Monoisotopic: 267.067761987
Monoisotopic: 267.067761987
CAS号
729-99-7
ATC分类
J01E 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
Sulfamoxole is a sulfonamide antibacterial.
生产厂家
封装厂家
参考
Synthesis Reference | Not Available |
General Reference |
|
剂型
规格
化合物类型
Type | small molecule |
Classes | Not Available |
Substructures | Not Available |
适应症
药理
Indication | For the treatment of bacterial infection. |
Pharmacodynamics | Sulfamoxole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. |
Mechanism of action | Sulfamoxole is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. |
Absorption | Not Available |
Volume of distribution | Not Available |
Protein binding | Not Available |
Metabolism |
Not Available
|
Route of elimination | Not Available |
Half life | Not Available |
Clearance | Not Available |
Toxicity | Oral Rat LD50: > 12500 mg/kg; Intravenous Mouse LD50: 1 g/kg |
Affected organisms |
|
Pathways | Not Available |
理化性质
Properties | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
State | solid | ||||||||||||||||||||||||||||||||||||||||||
Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
Predicted Properties |
|
药物相互作用
食物相互作用
Not Available